Online citations, reference lists, and bibliographies.
← Back to Search

East Indian Sandalwood Oil (EISO) Alleviates Inflammatory And Proliferative Pathologies Of Psoriasis

M. Sharma, C. Levenson, I. Clements, Paul Castella, K. Gebauer, M. Cox
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Psoriasis, a chronic inflammatory skin disease marked by hyper proliferation and aberrant differentiation of keratinocytes, affects 2–3% of the world’s population. Research into the pathogenesis of psoriasis has been hampered by the lack of models that accurately reflect the biology of the psoriatic phenotype. We have previously reported that East Indian Sandalwood oil (EISO) has significant anti-inflammatory properties in skin models and hypothesized that EISO might provide therapeutic benefit to psoriasis patients due to its anti-inflammatory and anti-proliferative properties. Here we present interim results from an on-going proof-of-concept Phase 2 clinical trial in which topically applied EISO is demonstrating to be well tolerated and helpful in alleviating mild to moderate psoriasis symptoms. This led us to evaluate the ability of EISO to affect the psoriatic phenotype using MatTek Corporation reconstituted organotypic psoriatic and normal human skin models. EISO had no impact on the phenotype of the normal skin tissue model, however, EISO treatment of the psoriasis tissue model reverted psoriatic pathology as demonstrated by histologic characterization and expression of keratinocyte proliferation markers, Ki67 and psoriasin. These phenotypic affects correlated with suppressed production of ENA-78, IL-6, IL-8, MCP-1, GM-CSF, and IL-1β. Demonstration of the ability of EISO to abrogate these psoriasis symptoms in well-characterized in vitro psoriatic tissue models, supports the hypothesis that the clinically observed symptom alleviation is due to suppression of intrinsic tissue inflammation reactions in afflicted lesions. This study presents a systematic approach to further study the underlying mechanisms that cause psoriasis, and presents data supporting the potential of EISO as a new ethnobotanical therapeutic concept to help direct and accelerate the development of more effective therapies.
This paper references
10.1111/j.1346-8138.2005.tb00878.x
Review of a Treatment for Psoriasis Using Herose, a Botanical Formula
Tony Tang Yuqi (2005)
Pathogenesis and therapy.
H. P. Teglbjaerg (1954)
10.1111/1523-1747.EP12294284
Psoriasin: a novel chemotactic protein.
T. Jinquan (1996)
10.1002/ptr.5080
Suppression of Lipopolysaccharide‐stimulated Cytokine/Chemokine Production in Skin Cells by Sandalwood Oils and Purified α‐santalol and β‐santalol
M. Sharma (2014)
10.1016/0031-9422(81)83047-6
Identification of Trans-β-santalol and epi-cis-β-santalol in east indian sandalwood oil☆
P. A. Christenson (1981)
10.1016/J.FCT.2007.09.092
Safety assessment of sandalwood oil (Santalum album L.).
G. Burdock (2008)
10.1155/2013/980419
Promising New Treatments for Psoriasis
Sarah Dubois Declercq (2013)
A role for T cell-derived interleukin 22 in psoriatic skin
F X (2007)
10.1155/2014/283617
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
L. Hsu (2014)
10.1016/j.bcp.2012.01.001
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
P. Schafer (2012)
10.1111/j.1346-8138.2011.01483.x
Antimicrobial peptides in the pathogenesis of psoriasis
S. Morizane (2012)
Skin cancer chemoprevention by alpha-santalol
X. Zhang (2011)
10.1038/jid.2008.268
The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption.
R. Gläser (2009)
10.1093/CARCIN/BGH325
Skin cancer chemopreventive agent, {alpha}-santalol, induces apoptotic death of human epidermoid carcinoma A431 cells via caspase activation together with dissipation of mitochondrial membrane potential and cytochrome c release.
M. Kaur (2005)
alpha - and betasantalols directly interact with tubulin and cause mitotic arrest and cytotoxicity in oral cancer cells
B. Lee (2015)
10.1016/j.jaad.2009.08.026
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
A. Menter (2010)
10.1111/bjd.14718
Psoriasin (S100A7) promotes stress‐induced angiogenesis
J. Vegfors (2016)
Psoriasis treatment: traditional
M. Lebwohl (2005)
Frontiers in Pharmacology | www.frontiersin
10.1016/S0140-6736(07)61129-5
Current and future management of psoriasis
A. Menter (2007)
10.3109/09546634.2013.865009
The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
R. Langley (2015)
10.1111/1523-1747.EP12484041
Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin.
P. Madsen (1991)
Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne.
R. Moy (2012)
Th 17 cytokines interleukin ( IL )17 and IL22 modulate distinct inflammatory and keratinocyteresponse pathways
K. E. Nograles (2008)
10.1038/jid.2009.399
Circulating Th17, Th22, and Th1 cells are increased in psoriasis.
S. Kagami (2010)
10.1016/S0140-6736(12)60642-4
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
K. Papp (2012)
This is an Open Access article distribut...
(2007)
alphaand beta-santalols directly interact with tubulin and cause mitotic arrest and cytotoxicity in oral cancer cells
B Lee (2015)
The psoriatic patient profile
G. Malara (2011)
10.1111/j.1365-2249.2007.03511.x
A role for T cell‐derived interleukin 22 in psoriatic skin inflammation
K. Boniface (2007)
10.1038/nature05663
Pathogenesis and therapy of psoriasis
M. A. Lowes (2007)
10.1007/BF02505229
Differential expression of CRABP II, psoriasin and cytokeratin 1 mRNA in human skin diseases
B. Algermissen (2006)
Angiogenesis drives
R. Heidenreich (2009)
Tetrahedron
A randomized phase 2 a efficacy and safety trial of the topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
W. C. Ports (2013)
10.1038/ni1497
Development, cytokine profile and function of human interleukin 17–producing helper T cells
N. Wilson (2007)
10.1016/J.TET.2006.04.072
New antitumor sesquiterpenoids from Santalum album of Indian origin
T. Kim (2006)
10.1067/MJD.2003.103
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
G. Weinstein (2003)
The psoriatic patient profile for infliximab.
P. Gisondi (2011)
Safety assessment of sandalwood oil
G. A. 03511.x Burdock (2008)
10.1111/j.0906-6705.2006.00435.x
Glucocorticoid therapy‐induced skin atrophy
S. Schoepe (2006)
10.1111/j.1365-2133.2008.08769.x
Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways
K. E. Nograles (2008)
Topically used herbal products
A. 2009.00669.x Herman (2016)
Development, cytokine profile and function
Mattson (2007)
psoriasis. ScientificWorldJournal 2013:980419
C. Dwivedi (2006)
10.1201/B17244-4
Natural Products Sources
R. Cooper (2014)
10.1084/jem.20061308
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides
S. Liang (2006)
10.1111/j.1476-5381.2010.00702.x
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
W. Weger (2010)
Current status and new developments in the treatment
W. Weger (2010)
10.1111/j.1468-3083.2011.04059.x
In touch with psoriasis: topical treatments and current guidelines
G. Murphy (2011)
10.1159/000232303
Topical treatment of psoriasis.
Qurat ul Ain Kamili (2009)
10.1016/j.jaad.2008.02.040
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
A. Gottlieb (2008)
10.1097/ACI.0b013e3282ef869e
Interleukin-17 in inflammatory skin disorders
A. V. van Beelen (2007)
Clinical analysis of effctiveness of pyrithinone zine aerosol combined with tazarotene cream in the treatment of psoriasis
Li Yong-zhon (2008)
10.1111/bjd.12266
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
W. Ports (2013)
Endocr. Metab. Immune Disord. Drug Targets
The role of salicylic acid in the treatment of psoriasis doi: 10.1046/j.1365-4362 Psoriasis treatment: traditional therapy
M Lebwohl (1999)
10.1007/s00403-013-1316-y
Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis
S. Deng (2013)
10.1055/S-0042-115177
Topically Used Herbal Products for the Treatment of Psoriasis - Mechanism of Action, Drug Delivery, Clinical Studies.
A. Herman (2016)
Antimicrobial peptides in the pathogenesis
S. Morizane (2012)
10.1111/j.1468-3083.2009.03358.x
Topical corticosteroids in psoriasis: strategies for improving safety
E. Horn (2010)
10.4155/fmc.13.27
Amygdalin analogs for the treatment of psoriasis.
J. Pérez (2013)
A role for T cell-derived interleukin 22 in psoriatic skin inflammation Safety assessment of sandalwood oil (Santalum album L.)
K Boniface (2007)
10.1186/1476-4598-12-147
α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway
S. Saraswati (2013)
10.1007/s40265-014-0191-y
Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
P. Mease (2014)
Promising new treatments
S. Dubois Declercq (2013)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
10.2174/187153012802002901
Classical to current approach for treatment of psoriasis: a review.
Mahfoozur Rahman (2012)
10.12703/P6-4
Advances in treating psoriasis
K. Belge (2014)
10.1021/np200906s
Natural products as sources of new drugs over the 30 years from 1981 to 2010.
D. Newman (2012)
10.1021/NP040188Q
Anti-Helicobacter pylori compounds from Santalum album.
Toshimasa Ochi (2005)
10.1097/MOP.0b013e328362c3f6
New therapies under development for psoriasis treatment
Martha-Estrella García-Pérez (2013)
10.1007/s00281-015-0545-x
Cutaneous immunology: basics and new concepts
A. S. Yazdi (2015)
10.1038/sj.jid.5701213
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.
M. A. Lowes (2008)
10.1136/ard.2004.030791
Psoriasis treatment: traditional therapy
M. Lebwohl (2005)
10.1093/CARCIN/BGL058
Chemopreventive effects of alpha-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice.
C. Dwivedi (2006)
10.1517/13543784.2010.504714
Novel investigational drugs for basal cell carcinoma
Po-Lin So (2010)
Chemopreventive effects of alphasantalol on ultraviolet B radiation - induced skin tumor development in SKH1 hairless mice
C. Dwivedi (2006)
10.1111/j.1365-2613.2009.00669.x
Angiogenesis drives psoriasis pathogenesis
R. Heidenreich (2009)
Immunol
Psoriasis--pathophysiology, conventional, and alternative approaches to treatment.
M. Traub (2007)
10.1186/1477-7525-11-82
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study
V. Strand (2013)
Cutaneous immunology: basics
A. S. doi 10.1038ni1497 Yazdi (2016)
Topical herbal
S. Deng (2013)
Th17 cytokines interleukin
M. Farinas (2008)
10.1073/PNAS.86.16.6367
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes.
R. M. Grossman (1989)



This paper is referenced by
10.1186/s12906-020-02898-4
Identification of essential oils with activity against stationary phase Staphylococcus aureus
S. Xiao (2020)
10.1002/cbdv.201800405
Wound Pathogens: Investigating Antimicrobial Activity of Commercial Essential Oil Combinations against Reference Strains
A. Orchard (2018)
Crystallographic Studies Of Terpene Synthases: Important Enzymes That Synthesize Antibiotic And Biofuel Precursors, Aromatic Essential Oil Compounds And Anti-Cancer Derivatives
P. N. Blank (2019)
10.1007/s40495-019-00195-4
Sandalwood Oil for the Chemoprevention of Skin Cancer: Mechanistic Insights, Anti-inflammatory, and In Vivo Anticancer Potential
Rachita Jain (2019)
10.1101/727883
Identification of essential oils with activity against stationary phase Staphylococcus aureus
Shuzhen Xiao (2019)
10.1039/c8ra05195j
East Indian sandalwood (Santalum album L.) oil confers neuroprotection and geroprotection in Caenorhabditis elegans via activating SKN-1/Nrf2 signaling pathway† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra05195j
A. Mohankumar (2018)
10.1111/ics.12456
The in vitro antimicrobial evaluation of commercial essential oils and their combinations against acne
A. Orchard (2018)
10.1016/B978-0-12-810545-0.00005-X
In vitro models of psoriasis
B. Roy (2018)
10.1007/s00403-020-02056-3
Small molecules under development for psoriasis: on the road to the individualized therapies
Cervantes-Durán Claudia (2020)
10.1021/acs.biochem.7b00895
Substitution of Aromatic Residues with Polar Residues in the Active Site Pocket of epi-Isozizaene Synthase Leads to the Generation of New Cyclic Sesquiterpenes.
P. N. Blank (2017)
10.1080/14786419.2017.1399387
Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review
A. Bommareddy (2019)
10.3389/fphar.2018.00200
East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease
M. Sharma (2018)
10.3389/fcimb.2019.00007
Bacterial Dysbiosis and Translocation in Psoriasis Vulgaris
Maria J. E. Visser (2019)
Semantic Scholar Logo Some data provided by SemanticScholar